Venture Capital

Why Early Stage Medical Device Deals Aren’t as Bad as You May Think: Interview with Mike Carusi, General Partner at Lightstone Ventures

Warren Buffet is often quoted as stating, “The best time to be greedy is when others are fearful.” But can this same concept apply to the medtech space?

Can limited partners (the investors in a venture fund) be sold on the idea of bankrolling early-stage medical device companies?

In this interview with Mike Carusi, General Partner at Lightstone Ventures, we learn why his firm believes the current medtech environment represents an incredible investment opportunity.

Interview Highlights with Mike Carusi

  • Because of the challenges involved with raising money for early-stage medtech deals, will there be a large innovation gap in 7-10 years?
  • Is there any sort of mandate within large strategics to keep the medtech ecosystem alive?
  • For those “bloated” medical device startups that have raised $100+ million, how much pressure are they under?
  • Why early-stage medical device companies should look at biotech and pharma in order to discover creative ways to fund companies.
  • Will the build-to-suit (“exclusive incubator”) trend continue?
  • VC firms win by trying to hit home runs versus singles.  But if you can be efficient with capital, can hitting singles be a viable model?  In other words, can Fred Khosravi’s success be duplicated?
  • Is there room left for the traditional model of incremental product improvements (with minimal clinical data) at higher market prices? AKA the “fast follower” approach.
  • Are we in a renal denervation bubble?
  • How does a medtech engineer, physician, or entrepreneur get the attention of Mike and his VC colleagues?
  • What are medical device acquirers looking for in pre-revenue startups?  In other words, what markets should startups be pursuing?
  • Best practices for “de-risking” a potential acquisition.
  • How Mike’s early experience in sales helped him throughout his medical device career.

Listen to the Interview with Mike Carusi

Read the Interview with Mike Carusi

Download a copy of the interview transcript right here.

More About Mike Carusi

Mike is a General Partner and Team Leader of Lightstone Ventures. He focuses on biopharmaceutical and medical device investments out of the firm’s Palo Alto office. Mike also joined Advanced Technology Ventures in 1998 and serves as a General Partner. His representative investments include Altura Medical, Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID.AX), GluMetrics, Holaira, MicroVention (acquired by Terumo), NeuroVista, Plexxikon (acquired by Daiichi Sankyo), PowerVision, TranS1 (NASDAQ: TSON), and Second Genome.

Featured on the 2011 Forbes Midas List of top technology investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare-related conferences and trade shows. He serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, sits on the Tuck MBA Advisory Board, and is an advisory board member to the UCSF/Berkeley Venture Innovation Program.

Mike holds an M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College and a B.S. from Lehigh University.

You May Like These Articles

  • Recent
  • Featured
  • Related

How to Win with Contract Manufacturers: Interview with Travis Sessions, CEO of Biomerics

In this interview with Travis Sessions, CEO of Biomerics and Managing Partner of Med Venture Holdings, we discuss critical things to look for when identifying and working with contract manufacturers.

Clinical Trials as Revenue Drivers: Interview with Matthew Amsden, CEO of ProofPilot

In this discussion with Matthew Amsden, learn about the importance and feasibility of virtual clinical trials, how they can potentially become a revenue driver, the origin story of ProofPilot, and why their hybrid model is so popular.

Why Practicing Strategic Patience is Critical for Medtech Entrepreneurs: Interview with Dr. Tej Singh, Founder of Fist Assist Devices

In this interview, Dr. Singh talks about the primary challenge that Fist Assist Devices is trying to solve, the origin story for their first product, and his approach to mapping out clinical trial strategies.

How Remote Testing Can Change the Game for Patients and Clinicians: Interview with Katherine Ward of Healthy.io

In this conversation with Katherine Ward, we cover what Healthy.io does for the broader healthcare community, lessons from the COVID-19 crisis, and the value of decentralized remote diagnostic screening.

Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular

In this interview, Bruce Shook discusses medical device insurance coverage and reimbursement, as well as advice for other healthcare entrepreneurs that need to raise money.

Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger

In this interview, the legendary Dr. John Simpson shares what drew him to the field of cardiology, his approach to building a medtech team, and why knowing your strengths and limitations is key to making a difference in the lives of others.

After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

In this interview with Duke Rohen, he discusses how he successfully led two early-stage medtech companies at the same time and the major lessons he learned raising money for 4 different medical device companies.

Having a Heart Attack? There’s an App for That! The Incredible Story of How Dr. David Albert Brought the ECG iPhone App to Market

In this interview with Dr. David Albert, we learn about his incredible journey in bringing the first iPhone ECG app to market with AliveCor.

Why Early Stage Medical Device Deals Aren’t as Bad as You May Think: Interview with Mike Carusi, General Partner at Lightstone Ventures

In this interview with medtech venture capitalist, Mike Carusi, he explains why early-stage medical device companies should look at biotech and pharma for creative ways to fund their companies.

Is Medtech Venture Capital Dead in the Water? Interview with Kevin Bitterman, Principal at Polaris Venture Partners

In this interview with Kevin Bitterman, we learn what medtech venture capitalists like to see in a startup and how these early-stage medical device companies can best position themselves for success.

How to Fund Medtech Startups in a Capital-Efficient Manner: Interview with Rich Ferrari, Managing Director of De Novo Ventures

In this interview with Rich Ferrari of De Novo Ventures, we learn more about the current state of medtech venture capital and the impact on medical device startups.

What it Takes to Get a Medtech VC to Say Yes: Interview with Lisa Suennen

In this interview with Lisa Suennen, we learn why medical device companies will need to adjust their business models to succeed in today's healthcare environment.

Success! Your membership is now active.